Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria

Abstract

Multidrug resistance in bacteria is an important issue and is increasing in frequency worldwide because of the limitations of therapeutic agents. From 2010 to 2019, 14 new systemic antibiotics received regulatory approval in the United States. However, few new antibiotics have been introduced in Republic of Korea to combat multidrug-resistant pathogens. Here, we introduce six novel antibiotics for Gram-positive bacteria and five for Gram-negative bacteria approved by the United States Food and Drug Administration and the European Medicines Agency from 2009 to October 2021, and recommend that they be approved for use in Republic of Korea at the earliest possible date.

Keywords

• anti-bacterial agents
• drug resistance
• multiple
• methicillin-resistant staphylococcus aureus
• carbapenem-resistant enterobacteriaceae
• antimicrobial stewardship